DE3481510D1 - Optisch aktive verbindungen mit antitassiver und zentral-sedativer wirkung, ein verfahren zu deren herstellung und diese enthaltende zusammensetzungen. - Google Patents

Optisch aktive verbindungen mit antitassiver und zentral-sedativer wirkung, ein verfahren zu deren herstellung und diese enthaltende zusammensetzungen.

Info

Publication number
DE3481510D1
DE3481510D1 DE8484116334T DE3481510T DE3481510D1 DE 3481510 D1 DE3481510 D1 DE 3481510D1 DE 8484116334 T DE8484116334 T DE 8484116334T DE 3481510 T DE3481510 T DE 3481510T DE 3481510 D1 DE3481510 D1 DE 3481510D1
Authority
DE
Germany
Prior art keywords
antitassive
central
production
optically active
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8484116334T
Other languages
English (en)
Inventor
Massimiliano Borsa
Giancarlo Tonon
Salvatore Malandrino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Application granted granted Critical
Publication of DE3481510D1 publication Critical patent/DE3481510D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20Free hydroxyl or mercaptan
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8484116334T 1983-12-29 1984-12-27 Optisch aktive verbindungen mit antitassiver und zentral-sedativer wirkung, ein verfahren zu deren herstellung und diese enthaltende zusammensetzungen. Expired - Lifetime DE3481510D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT24430/83A IT1203721B (it) 1983-12-29 1983-12-29 Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono

Publications (1)

Publication Number Publication Date
DE3481510D1 true DE3481510D1 (de) 1990-04-12

Family

ID=11213495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484116334T Expired - Lifetime DE3481510D1 (de) 1983-12-29 1984-12-27 Optisch aktive verbindungen mit antitassiver und zentral-sedativer wirkung, ein verfahren zu deren herstellung und diese enthaltende zusammensetzungen.

Country Status (6)

Country Link
US (2) US4699911A (de)
EP (1) EP0147847B1 (de)
JP (3) JPS60252474A (de)
AT (1) ATE50767T1 (de)
DE (1) DE3481510D1 (de)
IT (1) IT1203721B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837025A (en) * 1988-03-25 1989-06-06 Laboratoires D'hygiene Et De Dietetique Self-adhesive device for the percutaneous administration of an active ingredient
NL8801622A (nl) * 1988-06-25 1990-01-16 Stamicarbon Bereiding van enantiomeren van dropropizine.
IT1226570B (it) * 1988-08-01 1991-01-24 Bidachem Spa Procedimento di preparazione della levo- e destro-dropropizina
IT1231158B (it) * 1989-07-20 1991-11-19 Dompe Farmaceutici Spa Procedimento per la risoluzione ottica della dropropizina.
EP1022025A3 (de) * 1991-06-26 2002-06-05 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von Erbrechen, Übelkeit und anderen Störungen unter Verwendung von optisch reinem S(+)-ondansetron
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
IT1254452B (it) * 1992-02-14 1995-09-25 Dompe Farmaceutici Spa N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
IT1254993B (it) * 1992-06-24 1995-10-11 Procedimento per la preparazione degli enantiomeri della dropropizina
CA2371822A1 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
IT1318650B1 (it) * 2000-07-28 2003-08-27 Dompe Spa 1,3-diossolani ad attivita' antitosse.
IT1318651B1 (it) * 2000-07-28 2003-08-27 Dompe Spa Sintesi di (+-)1,3-diossolani e loro risoluzione ottica.
CN102805746B (zh) * 2011-06-02 2016-02-10 湖南九典制药股份有限公司 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
MX2017014725A (es) * 2017-11-16 2019-05-17 Productos Farm S A De C V Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE601394A (de) *
US3163649A (en) * 1964-12-29 Substituteb phenyl-piperazine
BE601794A (fr) * 1960-03-24 1961-09-25 Gabriel Co Mécanisme distributeur
GB938646A (en) * 1961-03-16 1963-10-02 Henri Morren New piperazine derivatives
NL275711A (de) * 1962-03-15
IT1210639B (it) * 1981-02-25 1989-09-14 Menarini Sas Prodotto: 3(4-fenil1piperazinio-1-il)-1,2-propandiolo 3(teofillin-7-il)-1propansolfonato,utilizzabile in terapia,e relativo procedimento di fabbricazione

Also Published As

Publication number Publication date
EP0147847B1 (de) 1990-03-07
EP0147847A2 (de) 1985-07-10
US4764515A (en) 1988-08-16
JPH058688B2 (de) 1993-02-02
IT1203721B (it) 1989-02-23
EP0147847A3 (en) 1986-11-26
ATE50767T1 (de) 1990-03-15
JPH05221864A (ja) 1993-08-31
JPH05222019A (ja) 1993-08-31
JPH0662416B2 (ja) 1994-08-17
JPS60252474A (ja) 1985-12-13
JPH0670027B2 (ja) 1994-09-07
US4699911A (en) 1987-10-13
IT8324430A0 (it) 1983-12-29

Similar Documents

Publication Publication Date Title
ATE7697T1 (de) Substituierte pyrazinyl-1,2,4-oxadiazol-5-one, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
DE3381772D1 (de) Substituierte azabicyclo-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO174239C (no) Fremgangsmåte for fremstilling av et oralt, farmasöytisk preparat
DE3481510D1 (de) Optisch aktive verbindungen mit antitassiver und zentral-sedativer wirkung, ein verfahren zu deren herstellung und diese enthaltende zusammensetzungen.
DE58904674D1 (de) 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt.
ATE1238T1 (de) Neue 1,4-dihydropyridinverbindungen, verfahren zu ihrer herstellung, die genannten verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser arzneimittel.
ATE60582T1 (de) Oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte.
DE68913924D1 (de) Verfahren zur Herstellung von optischen Fasern durch Lösungsdotierungstechnik.
ATE290T1 (de) Fluorhaltige 1,4-dihydropyridine, diese enthaltende arzneimittel sowie verfahren zu ihrer herstellung.
ATA197283A (de) Verfahren zur herstellung von beta, gamma -dihydropolyprenylalkoholderivaten
NO179612C (no) Analogifremgangsmåte for fremstilling av 3-arylkarbonyl-1-aminoalkyl-1H-indol-forbindelser
AT337192B (de) Verfahren zur herstellung von optisch aktiven 1,4-benzodiazepin-2-onen
ATE1241T1 (de) Verfahren zur herstellung von 4,5-perfluor-1,3-dioxolanen.
AT363936B (de) Verfahren zur herstellung von neuen cyproheptadinderivaten und von deren pharmazeutisch verwendbaren salzen sowie optischen isomeren
DK143445C (da) Analogifremgangsmaade til fremstilling af racemiske eller optisk aktive substituerede 1,1-diphenyl-3-amino-propanol-forbindelser
DE69710909D1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
PT74721B (de) Oxindol-derivate verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung
DE3874577D1 (de) Optisch aktive benzoabkoemmlinge, verfahren zu deren herstellung und sie als wirkstoff enthaltende fluessigkristalline zusammensetzungen und optische schaltelemente.
ATE37369T1 (de) Eine thiazinverbindung, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3870065D1 (de) Zusammensetzungen von polyarylalkanoligomeren, verfahren zu deren herstellung.
PL266361A1 (en) Method for manufacturing new tetrahydrobenyotiazole derivatives
ATE31928T1 (de) Acylamino-4-aza-1-adamantane, verfahren zu ihrer herstellung und ihre anwendung in der therapeutik.
DE3766418D1 (de) Substituierte benzimidazolylthiomethylbenzothiazol-derivate und deren salze, verfahren zu deren herstellung, deren medizinische anwendung und diese enthaltende zusammenstellungen.
ATE100102T1 (de) Substituierte derivate von 20,21dinoreburnamenin, verfahren zur herstellung und so hergestellte zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
DK539079A (da) Fremgangsmaade til fremstilling af isoxazolderivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition